Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Cagrilintide alone: -11.5% REDEFINE 2 (obesity + T2D): Phase 3, 68 weeks, ~1,200 patients
doi: 10.1002/dmrr.3070 Summary Keywords GLP-1 receptor agonists, thyroid disorders, thyroid cancer, meta-analysis, randomized controlled trials Citation Hu W, Song R, Cheng R, Liu C, Guo R, Tang W, Zhang J, Zhao Q, Li X and Liu J (2022) Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials
continued the medication stopped the medication SURMOUNT-4 trial Zepbound (tirzepatide) Same study design, different medication, similar pattern
If you are interested in learning more about this important peptide, call to schedule a consultation and discussion about whether this peptide might be a good option for you on your journey to optimal health and wellness.
US$ 28.14
US$ 27.20
US$ 24.19
